Loading...
•
Sep 30, 2024
Evofem Biosciences Q3 2024 Earnings Report
Evofem Biosciences announced Q3 2024 financial results, improved loss from operations and acquired SOLOSEC.
Key Takeaways
Evofem Biosciences reported a decrease in net product sales to $4.5 million compared to $5.1 million in the prior year period. However, the operating loss improved to $2.4 million compared to an operating loss of $3.6 million in the third quarter of 2023.
Net product sales were $4.5 million, a 12% decrease compared to the prior year period.
Operating loss improved to $2.4 million, compared to an operating loss of $3.6 million in the prior year period.
Acquired SOLOSEC, a single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections.
Forged commercial agreement for Phexxi in the Middle East.
Evofem Biosciences
Evofem Biosciences
Forward Guidance
The press release includes forward-looking statements regarding the Company’s anticipated financial performance, expected timing of the regulatory submission to the UAE Ministry of Health, and the likelihood of success and anticipated timing to close the contemplated Aditxt transaction.